Drug Type Small molecule drug |
Synonyms TAS 117 |
Target |
Mechanism Proto-oncogene proteins c-akt inhibitors(Proto-oncogene proteins c-akt inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC26H24N4O2 |
InChIKeyAIFGVDXMHWGOGJ-DIVCQZSQSA-N |
CAS Registry1402602-94-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | KR | 21 Nov 2017 | |
Metastatic Solid Tumor | Phase 1 | US | 31 Mar 2021 | |
Metastatic Solid Tumor | Phase 1 | AT | 31 Mar 2021 | |
Metastatic Solid Tumor | Phase 1 | FR | 31 Mar 2021 | |
Metastatic Solid Tumor | Phase 1 | GB | 31 Mar 2021 |
NCT04770246 (ESMO2022) Manual | Phase 2 | HR-positive/HER2-low Solid Tumors PTEN-inactivating mutations | 16 | owrcjnjyrh(wxfppwidri) = hxteluxfzi uehldxpuys (uhhrswlmge ) View more | Positive | 10 Sep 2022 | |
Phase 2 | 13 | avimbjhfxv(xlsafjqfbp) = hivzlwropj xsblouowmy (zubwhkqxzw ) View more | - | 01 Jul 2021 | |||
Phase 1 | 42 | bhvlagklap(pafmzcwprd) = lozicdjnat blssskcvxh (fuhwrtbtcv ) View more | Positive | 28 Sep 2019 |